hIL-15 NOG小鼠, hIL-15 NOG Mice - 维通利华

产品服务 > 实验动物模型 > 查找动物模型品系

hIL-15 NOG Mice

品系代码：

414

专业名称：

NOD.Cg-Prkdc^scidIL2rg^tm1SugTg(CMV-IL2/IL15)1-1Jic/JicCrl

小鼠,免疫缺陷模型免疫学,肿瘤学同类系,免疫缺陷

【CIEM正式授权】表达人源细胞因子IL-15

品系来源

应用特性

价格规格

应用文献

品系来源

hIL-15 NOG小鼠由日本中央实验动物研究所（CIEM）培育而成。CIEM Mamoru Ito实验室通过将CMV启动子控制的含有hIL-15 cDNA的DNA转基因载体（带有hIL-2信号肽）显微注射到NOD/ShiJic-Il2rg小鼠的受精卵中，构建出Founder品系。该Founder再与NOG小鼠回交，建立了稳定的hIL-15 NOG小鼠。

✈ 2020年，维通利华从CIEM引入该品系。

☑ 拓展阅读：不同NOG衍生品系的特点与应用场景解析

☑ 拓展阅读：hIL-15 NOG小鼠在γδ T细胞治疗研究中的应用案例

☑ 拓展阅读：NK细胞研发加速计划：看hIL-15 NOG小鼠推动细胞疗法新进展

☑ 研发加速计划：点击立即获取hIL-15 NOG优惠名额

科研必备：不同NOG衍生品系的特点与应用场景解析

应用特性

研究用途：

非常适用于抗体依赖性的NK细胞毒性（ADCC）研究。
可用于基于NK细胞的肿瘤免疫疗法研究。
可用于癌症、传染病、免疫学、再生医学、人类免疫系统移植等研究。

特性：

毛色：白化

除了NOG小鼠的特性外，还具备以下特性：

表达人源细胞因子IL-15。
与NOG小鼠相比，huHSC-CD34+移植hIL-15 NOG小鼠后，人的NK细胞重建率更高，但寿命相对缩短。
huHSC-CD34+移植hIL-15 NOG小鼠后产生的人源NK细胞，能够表达各种NK细胞受体，刺激后也能够产生颗粒酶A和穿孔素。
直接移植人外周血单个核细胞来源的CD56+NK细胞（huPBMC-NK），也会有NK细胞的重建及扩增。

价格规格

品系代码	品系名称	日/周龄	性别	VAF/SPF级	Elite/SPF级
414	hIL-15 NOG	1-10周	雌		1290

*以上规格与价格自2026年1月1日至2026年12月31日有效。

应用文献

hIL-15 NOG Publications

Authors	Year	Paper Title	Keywords
Hiura S, et al	2025	Selective agonists of KIR and NKG2A to evade missing self response of natural killer cells	Allotransplantation, NK cells
Bruna Taciane da Silva Bortoleti, et al.	2025	A monoclonal antibody that inhibits the shedding of CD16a and CD16b and promotes antibody-dependent cellular cytotoxicity against tumors	Tumour immunology, Innate lymphoid cells, Antibodies
Whalen KA, et al.	2025	CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity	CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity
Hiura S, et al	2025	Selective agonists of KIR and NKG2A to evade missing self response of natural killer cells	Allotransplantation, NK cells
Joel S. Benjamin, et al.	2025	23ME-01473, an Fc Effector–Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell–Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation	UL16-binding protein 6 (ULBP6), 2NKG2D，23ME-01473，NK cell
Whalen KA, et al.	2025	CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity	CLN-619 ，NK cell, NKG2D, CD16A
Rafael Blanco-Domínguez, et al.	2025	Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer	Delta One T (DOT) cells， Vδ1⁺γδ T cell，Colorectal cancer (CRC)，tumor-infiltrating lymphocytes，NKG2D ligands
Odd L Gammelgaard, et al.	2024	Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis	Adoptive cell transfer therapy, Anti-PDL1, triple-negative breast cancer, MDA-MB-231
Émilie Degagné, et al.	2024	High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models	BCMA, allogenei CAR-T, GvHD
Shahryar Khoshtinat Nikkhoi, et al.	2024	Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice	bispecific killer cell engager, BiKE:E5C1, NK cell, HER-2+,
Lisa A. King, et al.	2024	Vd2 T-cell engagers bivalent for Vd2-TCR binding provide antitumor immunity and support robust Vg9Vd2 T-cell expansion	Vg9Vd2 T-cells, bispecific T-cell engager, single domain antibody, expansion, immunotherapy, cancer
Khoshtinat Nikkhoi S, et al.	2024	Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice	HER2, CD16a, BiKE:E5C1, ADCC, laNK92, NK
Jian‑Xin Cui, et al.	2023	L-kynurenine induces NK cell loss in gastric cancer microenvironment via promoting ferroptosis	NK cell, Gastric cancer, Tumor microenvironment, L-kynurenine, Ferroptosis
Jens Pahl, et al.	2023	AFM13 enhances the anti-tumor activity of AB-101 towards CD30+ tumors, conferring tumor growth control in vivo.	AFM13，AB-101，ADCC, NK, CD30/CD16A，Bispecific antibody
Sumin Jo, et al.	2022	Endowing universal CAR T-cell with immuneevasive properties using TALEN-gene editing
Rodolfo Gonzalez, et al.	2022	CB-020, an Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic CAR-NK Cell Therapy, Engineered for Enhanced Activity Against Solid Tumors	CAR-NK, iPSC-derived, cell therapy, ROR1
Caruso, Simona et al.	2022	Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia	CAR-NK, AML, CD123, cell therapy
Eduardo Huarte, et al.	2021	Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models	NK cell, GvHD, JAK/STAT,
Jens Pahl, et al.	2021	AFM24 is a novel, highly potent, tetravalent bispecific EGFR/CD16A-targeting Innate Cell Engager (ICE®) designed for the treatment of EGFR-positive malignancies	BiAbs,CD16/EGFR, breast cancer, antibody-dependent cell-mediated cytotoxicity (ADCC), macrohphage-mediated antibody-dependent cellular phagocytosis (ADCP), Immuno-Oncology
Kevin R. Kipp, et al.	2021	BNZ-2, a dual specific IL15/IL21 inhibitor, rescues humanized NOG-IL15 transgenic mice from intestinal acute graft vs host disease without disrupting NK and CD8 T cell engraftment	IL15/IL21 inhibitor, GvHD, blood immunophenotyping, CD8+ T cell
Nina B. Horowitz, et al.	2021	Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies	innate lymphocyte cell (ILCs), NK cell, cancer immunotherapy, oncoimmunology, PDX, humanized
Ikumi Katano, et al.	2020	Improved Detection of in vivo Human NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Using a Novel NOG-FcγR-Deficient Human IL-15 Transgenic Mouse	ADCC, NK cell, humanized,
C.Rudulier, et al.	2020	In vivo Model Development for Genome-Edited T Cell Therapeutics	safety assessment, cell therapy
Anna Bunin, et al.	2019	Human transgenic IL-15 NOG mice reconstituted with human NK cells as a model for NK cell depletion	NK cell engraftment, ADCC, lymphoma
Paul Volden, et al.	2018	Cytokine-transgenic NOG mice engrafted with human peripheral blood cells support natural killer cell expansion	NK cell, cytotoxicity,
Ikumi Katano, et al.	2017	Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse	NK cell, ADCC, leukemia, K562, gastric cancer, HER-2, cell therapy, humanized
Ikumi Katano, et al.	2016	Human interleukin-15 transgenic NOG mice support the long-term maintenance of human mature NK cells from peripheral blood	NK cell, myelogenous leukemia, K562 basic data of HIL-15 NOG model